大唐药业(836433) - 2023 Q1 - 季度财报

Financial Performance - Operating revenue for the first quarter of 2023 reached CNY 54,218,554.17, representing a significant year-on-year growth of 90.34% from CNY 28,484,733.38 in the same period of 2022[11] - Net profit attributable to shareholders for the first quarter of 2023 was CNY 7,507,383.78, up 35.01% from CNY 5,560,706.73 in the previous year[11] - The net profit after deducting non-recurring gains and losses increased by 76.55% year-on-year, totaling CNY 6,556,365.88 compared to CNY 3,713,600.84 in Q1 2022[11] - Total operating revenue for Q1 2023 reached ¥54,218,554.17, a significant increase from ¥28,484,733.38 in Q1 2022, representing a growth of approximately 90.5%[36] - Net profit for Q1 2023 was ¥7,507,383.78, up from ¥5,560,706.73 in Q1 2022, reflecting a growth of approximately 34.9%[38] - The company's operating profit for Q1 2023 was 9,285,673.78, an increase from 7,377,144.09 in Q1 2022, representing a growth of approximately 25.0%[41] - Net profit for Q1 2023 reached 7,953,370.72, compared to 6,343,145.47 in Q1 2022, indicating a year-over-year increase of about 25.4%[41] Assets and Liabilities - Total assets as of March 31, 2023, amounted to CNY 647,557,603.95, a slight increase of 0.22% compared to CNY 646,151,101.29 at the end of 2022[11] - The company's current assets totaled CNY 279,072,405.33, down from CNY 308,402,565.52 at the end of 2022, representing a decrease of approximately 9.5%[28] - The company's total assets amounted to ¥643,171,678.51, slightly up from ¥641,323,978.78 in the previous period[34] - Total liabilities decreased to CNY 157,759,454.90 from CNY 163,510,076.69, a reduction of about 3.5%[30] - Current liabilities decreased to ¥143,374,569.57 from ¥154,886,303.12, showing a reduction of about 7.8%[34] - Non-current liabilities increased to ¥11,514,398.74 from ¥5,758,076.85, representing a growth of approximately 100.5%[34] - The total equity of the company rose to ¥488,282,710.20 from ¥480,679,598.81, indicating an increase of about 1.3%[34] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY 26,353,571.31, a decrease from a net inflow of CNY 66,622,261.16 in the same period last year[12] - The net cash flow from operating activities in Q1 2023 was -26,353,571.31, a decline from 66,622,261.16 in Q1 2022, indicating a negative shift in cash flow[45] - The cash flow from financing activities in Q1 2023 was 24,363,359.99, a recovery from a negative cash flow of -4,671,240.91 in Q1 2022[45] - Cash inflow from financing activities increased to $32.24 million in Q1 2023 compared to $7.25 million in Q1 2022[47] - The net cash flow from financing activities improved to $24.36 million in Q1 2023 from -$4.67 million in Q1 2022[47] Shareholder Information - The number of shareholders holding more than 5% of shares includes 呼和浩特市仁和房地产开发有限公司 with 59.13% ownership[21] - The company reported a basic earnings per share of CNY 0.03, a decrease of 25.00% compared to CNY 0.04 in the same period last year[12] - Basic earnings per share for Q1 2023 were ¥0.03, unchanged from Q1 2022[38] - Basic earnings per share for Q1 2023 were 0.03, down from 0.04 in Q1 2022, reflecting a decrease in profitability on a per-share basis[42] Operational Costs - Total operating costs for Q1 2023 were ¥46,672,715.03, compared to ¥25,082,838.87 in Q1 2022, indicating an increase of about 86.5%[37] - The total operating expenses for Q1 2023 were 64,836,994.19, compared to 38,027,515.41 in Q1 2022, showing an increase in operational costs[45] Research and Development - Research and development expenses for Q1 2023 were ¥1,286,808.01, compared to ¥1,487,606.90 in Q1 2022, showing a decrease of approximately 13.5%[37] - The company incurred research and development expenses of 1,191,958.30 in Q1 2023, slightly up from 1,125,728.74 in Q1 2022, indicating continued investment in innovation[41] Other Information - The company has fulfilled its commitments as disclosed in the public offering prospectus dated July 16, 2020[24] - The company has not engaged in any significant litigation or arbitration matters during the reporting period[24] - There were no new major acquisitions or mergers reported in the current quarter[25] - Non-recurring gains and losses for the first quarter totaled CNY 951,017.90 after tax, with government subsidies contributing CNY 660,417.98[15]